Abstract
Purpose of review
Urodynamic studies (UDS) remain the gold standard for the objective evaluation of lower urinary tract dysfunction, yet their diagnostic precision is frequently compromised by technical inconsistencies, interobserver variability, and methodological flaws in multicentre trials. This review maps these sources of variability and outlines strategies to restore reproducibility.
Recent findings
Variability spans technical acquisition errors, inconsistent patient coaching and terminology, interpretive subjectivity in trace reading, and trial-design flaws such as restrictive selection criteria and oversimplified diagnostic classification. Empirical surveys reveal marked heterogeneity in clinical practice across centres. Emerging solutions include structured quality assurance frameworks, standardized communication protocols, wireless catheter-free pressure sensors, and artificial intelligence pipelines achieving diagnostic accuracies of 80–95% for pattern recognition, though external validation and reference-standard circularity remain unresolved challenges.
Summary
Addressing these vulnerabilities through harmonized protocols, objective communication tools, centralized trace review, and validated AI support is essential to restore the credibility of urodynamic research and ensure tailored, evidence-based patient management.
Similar content being viewed by others
Data Availability
No datasets were generated or analysed during the current study.
References
Roberts BL, Tarcan T, Rodriguez P, Rogers RG, De EJB. Opportunity for ICS urodynamic standardization: sensation, rectal contractions, and involuntary detrusor contractions. Continence. 2024. https://doi.org/10.1016/j.cont.2024.101226.
Abdel-fattah M, Chapple C, Guerrero K, Dixon S, Cotterill N, Ward K, et al. Female urgency, trial of urodynamics as routine evaluation (FUTURE study): a superiority randomised clinical trial to evaluate the effectiveness and cost-effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms. Trials. 2021. https://doi.org/10.1186/s13063-021-05661-3.
Aiello M, Jelski J, Lewis A, Worthington J, McDonald C, Abrams P, et al. Quality control of uroflowmetry and urodynamic data from two large multicenter studies of male lower urinary tract symptoms. Neurourol Urodyn. 2020;39(4):1170–7. https://doi.org/10.1002/nau.24337.
van Leijsen SAL, Kluivers KB, Mol BWJ, Hout J, ’t, Milani AL, Roovers JPWR, et al. Value of urodynamics before stress urinary incontinence surgery: a randomized controlled trial. Obstet Gynecol. 2013;121(5):999–1008. https://doi.org/10.1097/AOG.0b013e31828c68e3 . PubMed PMID: 23635736.
Chew LE, Hannick JH, Woo LL, Weaver JK, Damaser MS. The future of urodynamics: innovations, challenges, and possibilities. Neurourol Urodyn. 2026. https://doi.org/10.1002/nau.70074.
Gammie A, Almeida F, Drake M, Finazzi Agrò E, Kirschner-Hermanns R, Lemos N, et al. Is the value of urodynamics undermined by poor technique?: ICI‐RS 2018. Neurourol Urodyn. 2018. https://doi.org/10.1002/nau.23978.
Rosier PFWM, Schaefer W, Lose G, Goldman HB, Guralnick M, Eustice S, et al. International Continence Society good urodynamic practices and terms 2016: urodynamics, uroflowmetry, cystometry, and pressure-flow study. Neurourol Urodyn. 2016;36(5):1243–60. https://doi.org/10.1002/nau.23124.
Kraus SR, Dmochowski R, Albo ME, Xu L, Klise SR, Roehrborn CG. Urodynamic standardization in a large-scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction. Neurourol Urodyn. 2010;29(5):741–7. https://doi.org/10.1002/nau.20825.
Pourghazi F, Chaudhary PK, Linder BJ, Alizad A, Fatemi M. Applications of artificial intelligence in urodynamic data interpretation: a narrative review. Neurourol Urodyn. 2026. https://doi.org/10.1002/nau.70308.
Saraluck A, Manonai J, Kijmanawat A, Wattanayingcharoenchai R. Artificial intelligence for urodynamic studies: systematic review of methods, performance, and clinical applications. BMC Med Inform Decis Mak. 2026. https://doi.org/10.1186/s12911-026-03592-0.
Nager CW, Brubaker L, Litman HJ, Zyczynski HM, Varner RE, Amundsen C, et al. A randomized trial of urodynamic testing before stress-incontinence surgery. N Engl J Med. 2012;366(21):1987–97. https://doi.org/10.1056/NEJMoa1113595.
Serati M, Topazio L, Bogani G, Costantini E, Pietropaolo A, Palleschi G, et al. Urodynamics useless before surgery for female stress urinary incontinence: are you sure? Results from a multicenter single nation database. Neurourol Urodyn. 2016;35(7):809–12. https://doi.org/10.1002/nau.22804.
Tarcan T, Finazzi-Agrò E, Kessler TM, Serati M, Solomon E, Rosier PFWM. How should prospective research be designed to legitimately assess the value of urodynamic studies in female urinary incontinence? Neurourol Urodyn. 2023;42(8):1639–46. https://doi.org/10.1002/nau.25273.
Abdel-Fattah M, Chapple C, Breeman S, Cooper D, Bell-Gorrod H, Kuppanda P, et al. Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms: FUTURE, a superiority RCT and economic evaluation. Health Technol Assess (Rockv). 2025;29(27):1–139. https://doi.org/10.3310/UKYW4923
Braga A, Espuña-Pons M, Serati M. Future study: when a trial could be confusing. Minerva Urol Nefrol. 2025. https://doi.org/10.23736/S2724-6051.25.06532-2.
Serati M, Tarcan T, Peyronnet B, Agrò EF. Re: invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms (FUTURE) in the UK: a multicentre, superiority, parallel, open-label, randomised controlled trial. Eur Urol. 2025. https://doi.org/10.1016/j.eururo.2025.05.016.
Serati M, Braga A, Rosier PFWM, de Wachter S, Uren A, Finazzi-Agrò E. Acceptability and perceived value of urodynamics from the patient perspective: A narrative review. Neurourol Urodyn. 2022;41(5):1065–73. https://doi.org/10.1002/nau.24932.
Peyronnet B, Mironska E, Chapple C, Cardozo L, Oelke M, Dmochowski R, et al. A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. Eur Urol. 2019;75(6):988–1000. https://doi.org/10.1016/j.eururo.2019.02.038.
Baboudjian M, Uleri A, Pradere B. Con: preoperative urodynamics still has a role for BPH patients after the UPSTREAM trial. French J Urol. 2024;34(6):102637. https://doi.org/10.1016/j.fjurol.2024.102637.
Rosato E, Mancini MC, Cerrelli G, Rocco FD, Orecchia L, Farullo G, et al. In how many patients urodynamics should be omitted? Data from a single-centre database on the basis of the upstream trial. Continence. 2025;14:101903. https://doi.org/10.1016/J.CONT.2025.101903.
Lewis P, Abrams P. Urodynamic protocol and central review of data for clinical trials in lower urinary tract dysfunction. BJU Int. 2000;85(s1):20–30. https://doi.org/10.1046/j.1464-410X.2000.00020.x.
Frainey BT, Majerus SJA, Derisavifard S, Lewis KC, Williams AR, Balog BM, et al. First in human subjects testing of the UroMonitor: a catheter-free wireless ambulatory bladder pressure monitor. J Urol. 2023;210(1):186–95. https://doi.org/10.1097/JU.0000000000003451.
Liu X, Zhong P, Chen D, Liao L. Real-time typical urodynamic signal recognition system using deep learning. Int Neurourol J. 2025;29(1):40–7. https://doi.org/10.5213/inj.2448430.215.
Funding
No funding was received for conducting this study.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by both authors. The first draft of the manuscript was written by Eleonora Rosato and Enrico Finazzi Agrò commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethical approval
Not applicable.
Human and Animal Rights
This article does not contain any studies with human or animal subjects performed by any of the authors.
Informed consent
Not applicable.
Data privacy
Not applicable.
Financial interests
Author Eleonora Rosato declare they have no financial interests.
Competing interests
Author Enrico Finazzi Agrò receives speaker honoraria from Recordati and Pierre Fabre and serves as a consultant and receives honoraria for speaking from Laborie.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Rosato, E., Finazzi Agrò, E. Standardization and Reproducibility in Multicentre Urodynamic Trials. Curr Bladder Dysfunct Rep 21, 40 (2026). https://doi.org/10.1007/s11884-026-00841-w
Received:
Accepted:
Published:
Version of record:
DOI: https://doi.org/10.1007/s11884-026-00841-w

